Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
Open Access
- 1 June 2022
- journal article
- Published by Elsevier BV in Cell Insight
- Vol. 1 (3), 100030
- https://doi.org/10.1016/j.cellin.2022.100030
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Discovery of Novel Dual Inhibitors of the Wild-Type and the Most Prevalent Drug-Resistant Mutant, S31N, of the M2 Proton Channel from Influenza A VirusJournal of Medicinal Chemistry, 2013
- Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised HostsClinical Infectious Diseases, 2010
- Antiviral Potential and Molecular Insight into Neuraminidase Inhibiting Diarylheptanoids from Alpinia katsumadaiJournal of Medicinal Chemistry, 2009
- Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic DriftScience, 2009
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomicsBioorganic & Medicinal Chemistry Letters, 2008
- High Temperature (30°C) Blocks Aerosol but Not Contact Transmission of Influenza VirusJournal of Virology, 2008
- Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutantsNature, 2008
- Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted DegradationJournal of the American Chemical Society, 2004
- Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and DegradationMolecular & Cellular Proteomics, 2003
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences of the United States of America, 2001